[Choice of neuroprotective therapy regimens in patients with chronic cerebral ischemia, taking into account the synergy of drug interactions].

Autor:	Gromova OA; Institute of Pharmacoinformatics, Moscow, Russia.; Center for Big Data Storage and Analysis of Moscow State University, Moscow, Russia., Torshin IY; Institute of Pharmacoinformatics, Moscow, Russia.; Center for Big Data Storage and Analysis of Moscow State University, Moscow, Russia., Putilina MV; Russian National Research Medical University, Moscow, Russia., Semenov VA; Kemerovo State Medical University, Kemerovo, Russia., Rudakov KV; Institute of Pharmacoinformatics, Moscow, Russia.; Center for Big Data Storage and Analysis of Moscow State University, Moscow, Russia.
Jazyk:	ruština
Zdroj:	Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2020; Vol. 120 (8), pp. 42-50.
DOI:	10.17116/jnevro202012008142
Abstrakt:	Objective: Optimization of the choice of neuroprotective treatment regimens in patients with chronic cerebral ischemia that takes into account the synergy of drug interactions gives the doctor an opportunity for personalized approach that increases the effectiveness of treatment. Material and Methods: Differential chemoreactomic analysis of the synergism of ethyl methyl hydroxypyridine succinate (EMHPS) and a number of monocomponent neuroprotective agents (piracetam, vinpocetine, citicoline, choline alfoscerate); proteomic analysis of polypeptide neuroprotectors (cerebrolysin, etc.); an expert analysis of multicomponent neuroprotector Cytoflavin. Results: Piracetam, citicoline (Neupilept) and choline alfoscerate (Cereton) effectively enhance the pharmacological properties of EMHPS and vice versa. Expert assessments of the synergism between the properties of EMHPS, polypeptide neuroprotectors (cerebrolysin) and other multicomponent drugs (cytoflavin), which are also used in adjuvant therapy with EMHPS, are presented. Conclusion: In real clinical practice, of particular interest is the objectification of the appointment of combined therapy regimens. This study indicates that EMHPS can provide a favorable background for maximizing the effectiveness of therapy when used with other drugs.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu